Form 8-K - Current report:
SEC Accession No. 0001493152-25-014057
Filing Date
2025-09-18
Accepted
2025-09-18 16:05:46
Documents
19
Period of Report
2025-09-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 40356
2 EX-10.1 ex10-1.htm EX-10.1 4199
3 GRAPHIC ex10-1_001.jpg GRAPHIC 659617
4 GRAPHIC ex10-1_002.jpg GRAPHIC 1091579
5 GRAPHIC ex10-1_003.jpg GRAPHIC 1036459
6 GRAPHIC ex10-1_004.jpg GRAPHIC 1126161
7 GRAPHIC ex10-1_005.jpg GRAPHIC 843293
8 GRAPHIC ex10-1_006.jpg GRAPHIC 122973
  Complete submission text file 0001493152-25-014057.txt   6933971

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE prph-20250918.xsd EX-101.SCH 3026
10 XBRL LABEL FILE prph-20250918_lab.xml EX-101.LAB 34239
11 XBRL PRESENTATION FILE prph-20250918_pre.xml EX-101.PRE 22366
21 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3716
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

EIN.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 251323485
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)